12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relvar Ellipta regulatory update

GlaxoSmithKline withdrew chronic obstructive pulmonary disease (COPD) as an indication on the Japanese NDA for Relvar Ellipta fluticasone furoate/vilanterol. The product - a once-daily, fixed dose combination of the inhaled corticosteroid fluticasone furoate and a long-acting adrenergic receptor beta 2 agonist (LABA) vilanterol administered with the dry powder Ellipta inhaler - is still under review for asthma, with a decision expected by year end.

GSK and partner...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >